Understanding Your Breast Cancer: The IHC pS2 Test
Facing a breast cancer diagnosis can feel overwhelming, but understanding your cancer’s specific characteristics is the first step toward effective treatment. The IHC pS2 test provides crucial information about your cancer’s hormone receptor status, helping you and your healthcare team make informed decisions about your care journey.
What the IHC pS2 Test Detects
The IHC pS2 test is a specialised immunohistochemistry examination that identifies whether your breast cancer cells have pS2 protein receptors. This protein is associated with estrogen-responsive tumours, and its presence helps determine if your cancer will likely respond to hormone-blocking therapies.
Think of it as learning your cancer’s “language” – understanding whether it communicates through hormone signals helps your doctors choose the most effective treatment approach specifically for your type of cancer.
Who Should Consider This Test
This test is particularly important for:
- Patients newly diagnosed with breast cancer
- Individuals with invasive ductal carcinoma
- Patients considering hormone therapy options
- Those wanting to understand their cancer’s treatment responsiveness
- Patients experiencing symptoms like breast lumps, skin changes, or nipple discharge
If you’re navigating breast cancer treatment decisions, this test provides the clarity needed to choose the right path forward.
Why This Matters for Your Health Journey
Knowing your pS2 status offers significant benefits:
- Personalised Treatment: Guides whether hormone therapy will be effective for your specific cancer
- Avoid Unnecessary Treatment: Prevents undergoing therapies that won’t benefit your cancer type
- Better Outcomes: Targeted treatments based on your cancer’s characteristics often lead to improved results
- Peace of Mind: Understanding your cancer’s nature reduces uncertainty during treatment planning
- Cost-Effective Care: Focuses resources on treatments most likely to work for you
Understanding Your Test Results
Your results will indicate whether your cancer cells show pS2 protein expression:
- Positive Result: Your cancer likely responds to hormone therapy, opening effective treatment options
- Negative Result: Your cancer may not benefit from hormone-blocking treatments, allowing focus on other approaches
Our pathologists provide clear, detailed reports that your oncologist will discuss with you, ensuring you fully understand what your results mean for your treatment plan.
Transparent Pricing – Investing in Your Health
| Test Description | Regular Price | Special Price |
|---|---|---|
| IHC pS2 Breast Cancer Hormone Receptor Test | ZAR 650 |
This affordable investment in your health provides information that could save thousands in ineffective treatments and, more importantly, guide you toward the most successful treatment path.
Why Trust Oracle Genomics
- Nationwide Coverage: Available across South Africa including Johannesburg, Cape Town, Durban, and Pretoria
- Expert Pathologists: Specialised oncology testing by experienced professionals
- Rapid Turnaround: Results typically within 5-7 days depending on sample type
- Accuracy Guarantee: State-of-the-art immunohistochemistry methods ensure reliable results
- Patient-Focused: Clear explanations and support throughout your testing journey
What You Need for Testing
We require tumour tissue preserved in 10% formal-saline or formalin-fixed paraffin-embedded block. Please also provide:
- Copy of your histopathology report
- Site of biopsy information
- Relevant clinical history
Samples can be shipped at room temperature to our accredited laboratories.
Take Control of Your Cancer Journey Today
Don’t leave your treatment decisions to chance. Understanding your cancer’s hormone receptor status through the IHC pS2 test provides the clarity needed for effective, personalised care.
Early testing means earlier treatment planning and better outcomes. Every day matters in your cancer journey.
Your health journey deserves the right information. Book your IHC pS2 test today at ZAR 650 and take the first step toward personalised, effective breast cancer treatment.